MedTrace Logo

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

NCT05167604 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-12-22

No results posted yet for this study

Summary

This clinical trial aims to explore the minimal residual disease (MRD) status of early NSCLC after curative surgery and the clinical outcomes of adjuvant chemotherapy. Next-generation sequencing technique will be used to examine the circulating tumor DNA (ctDNA) from MRD of 150 postoperative patients with stage IB-IIA NSCLC who received adjuvant chemotherapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Next-Generation Sequencing
  • Chemotherapy, Adjuvant
  • Neoplasm, Residual
  • Circulating Tumor DNA

Interventions

DRUG

Adjuvants, Pharmaceutic

Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status

Sponsors & Collaborators

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • Tao Jiang · Department of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-09-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167604 on ClinicalTrials.gov